Client Portfolio
genOway Serves Clients in 28 Countries Worldwide
Among those are 380 academic institutions, 13 EU framework projects, 170 Life Sciences companies, including 17 of the Top 20 pharma.
genOway as partner for EU research and innovation programmes (FP6, FP7, Horizon 2020)
- TO_AITION: Investigating mechanisms in CVD-depression comorbidity
- MATRICS: Multidisciplinary Approaches to Translational Research In Conduct Syndromes
- Aggressotype: Aggression subtyping for improved insight and treatment innovation in psychiatric disorders
- AtheroBCells: Targeting and exploiting B cell functions for treatment in cardiovascular diseases
- TACTICS: Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes
- MYORES: Multi-organismic approach to study normal and aberrant muscle development, function and repair
- RiskyCAD: Personalized diagnostics and treatment of high risk coronary artery disease patients
- AtheroRemo: Inflammation and Vascular Wall Remodeling in Atherosclerosis
- EUGeneHeart: Genomics of Cardiomyocyte Signalling to Treat and Prevent Heart Failure
- EURODIA: Functional genomics of Pancreatic beta cells and of tissues involved in control of the endocrine pancreas for prevention and treatment of type 2 diabetes
- EVI-GENORET: Functional genomics of the retina in health and disease
- EPI-Vector: Episomal vectors as gene delivery systems for therapeutic application